Viridian Therapeutics Files 8-K
Ticker: VRDN · Form: 8-K · Filed: Jul 15, 2024 · CIK: 1590750
Sentiment: neutral
Topics: 8-K, financial-reporting, corporate-filing
TL;DR
Viridian Therapeutics filed an 8-K with financial updates and exhibits.
AI Summary
Viridian Therapeutics, Inc. filed an 8-K on July 15, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc., is incorporated in Delaware and headquartered in Waltham, MA.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and exhibits, which provides transparency to investors about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate material changes or adverse events.
Key Numbers
- 001-36483 — SEC File Number (Identifies the company's filing with the SEC.)
- 47-1187261 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- Miragen Therapeutics, Inc. (company) — Former Company Name
- Signal Genetics, Inc. (company) — Former Company Name
- July 15, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Waltham, MA (location) — Business Address City/State
FAQ
What specific financial statements are included in this 8-K filing?
The filing indicates 'Financial Statements and Exhibits' are included, but the specific details of these statements are not provided in the excerpt.
What is the primary purpose of this 8-K filing?
The primary purpose is a Regulation FD Disclosure and the filing of Financial Statements and Exhibits.
When was Viridian Therapeutics, Inc. previously known by other names?
The company was formerly known as Miragen Therapeutics, Inc. (since February 13, 2017) and Signal Genetics, Inc. (since July 10, 2014).
Where is Viridian Therapeutics, Inc. headquartered?
The company's business address is located at 221 Crescent Street, Bldg. 17, Suite 401, Waltham, MA 02453.
What is the SIC code for Viridian Therapeutics, Inc.?
The Standard Industrial Classification code for Viridian Therapeutics, Inc. is 8071, which falls under SERVICES-MEDICAL LABORATORIES.
Filing Stats: 502 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-07-15 06:31:38
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value VRDN The Nasdaq Stock Mar
Filing Documents
- d840470d8k.htm (8-K) — 24KB
- d840470dex991.htm (EX-99.1) — 45KB
- g840470ex99_1p10g1.jpg (GRAPHIC) — 255KB
- g840470ex99_1p11g1.jpg (GRAPHIC) — 94KB
- g840470ex99_1p12g1.jpg (GRAPHIC) — 377KB
- g840470ex99_1p13g1.jpg (GRAPHIC) — 328KB
- g840470ex99_1p14g1.jpg (GRAPHIC) — 412KB
- g840470ex99_1p15g1.jpg (GRAPHIC) — 250KB
- g840470ex99_1p16g1.jpg (GRAPHIC) — 351KB
- g840470ex99_1p17g1.jpg (GRAPHIC) — 266KB
- g840470ex99_1p18g1.jpg (GRAPHIC) — 114KB
- g840470ex99_1p19g1.jpg (GRAPHIC) — 304KB
- g840470ex99_1p1g1.jpg (GRAPHIC) — 253KB
- g840470ex99_1p20g1.jpg (GRAPHIC) — 372KB
- g840470ex99_1p21g1.jpg (GRAPHIC) — 310KB
- g840470ex99_1p22g1.jpg (GRAPHIC) — 328KB
- g840470ex99_1p23g1.jpg (GRAPHIC) — 298KB
- g840470ex99_1p24g1.jpg (GRAPHIC) — 333KB
- g840470ex99_1p25g1.jpg (GRAPHIC) — 322KB
- g840470ex99_1p26g1.jpg (GRAPHIC) — 250KB
- g840470ex99_1p27g1.jpg (GRAPHIC) — 262KB
- g840470ex99_1p28g1.jpg (GRAPHIC) — 128KB
- g840470ex99_1p29g1.jpg (GRAPHIC) — 268KB
- g840470ex99_1p2g1.jpg (GRAPHIC) — 688KB
- g840470ex99_1p30g1.jpg (GRAPHIC) — 333KB
- g840470ex99_1p31g1.jpg (GRAPHIC) — 279KB
- g840470ex99_1p32g1.jpg (GRAPHIC) — 284KB
- g840470ex99_1p33g1.jpg (GRAPHIC) — 281KB
- g840470ex99_1p3g1.jpg (GRAPHIC) — 239KB
- g840470ex99_1p4g1.jpg (GRAPHIC) — 211KB
- g840470ex99_1p5g1.jpg (GRAPHIC) — 277KB
- g840470ex99_1p6g1.jpg (GRAPHIC) — 109KB
- g840470ex99_1p7g1.jpg (GRAPHIC) — 408KB
- g840470ex99_1p8g1.jpg (GRAPHIC) — 270KB
- g840470ex99_1p9g1.jpg (GRAPHIC) — 385KB
- g840470g0713234402794.jpg (GRAPHIC) — 3KB
- 0001193125-24-178820.txt ( ) — 13497KB
- vrdn-20240715.xsd (EX-101.SCH) — 3KB
- vrdn-20240715_lab.xml (EX-101.LAB) — 18KB
- vrdn-20240715_pre.xml (EX-101.PRE) — 11KB
- d840470d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Exhibit Description 99.1 Viridian Therapeutics, Inc. Investor Presentation, dated July 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viridian Therapeutics, Inc. Date: July 15, 2024 By: /s/ Stephen Mahoney Stephen Mahoney President, Chief Executive Officer, and Director